Agusto Foresees More Foreign Investments in Nigeria’s Healthcare System


By Adedapo Adesanya

One of Nigeria’s health tech companies, Remedial Health, has raised $4.4 million in seed funding to accelerate expansion across the country.

The funding support was provided by Global Ventures, Tencent, Y Combinator, Cathexis Ventures, LightSpeed ​​Venture Partners Scout Fund, Ventures Platform, Alumni Ventures, True Capital Management, and prominent angel investors such as Mr Guillaume Luccisano and Mr Christopher Golda.

The new capital will also provide access to credit for inventory purchases for its growing customer base of neighborhood pharmacies, Proprietary Patent Medicine Vendors (PPMVs) and hospitals in the country.

Since launching Remedial Health in 2021, the company has focused on delivering solutions for neighborhood pharmacies and PPMVs responsible for more than 80 per cent of the retail medicines sold in Africa.

According to Mr Samuel Okwuada, CEO and co-founder of Remedial Health, “The funds that we have raised and the strategic support from our investors will enable us to deliver the solutions to address various challenges that have hampered these businesses’ growth for many years , and make it easier to safeguard lives and livelihoods across the continent for years to come.”

Remedial Health provides various solutions, including its digital procurement and PMR (patient medication records) platforms that make it easier for neighborhood pharmacies, PPMVs and hospitals to access affordable and authentic retail medicines.

Healthcare providers can source vetted medications at prices the same or better than open-air medicine market prices – with 24-hour delivery to their practice via Remedial Health’s logistics network.

In addition to procurement, pharmacies and PPMVs can access credit to fund inventory purchases and provide loans and salary advances for employees.

Since January 2022, Remedial Health has seen a 600 per cent increase in sales volumes, and the company now covers 16 of Nigeria’s 36 states. This new funding will support the rollout of its services across the rest of Nigeria and lay the groundwork for expansion across Africa in 2023.

The impact of various global events over the last three years – from the COVID-19 pandemic to rising inflation – has led to a sharp increase in the price of medicines in Nigeria.

For neighborhood pharmacies and Proprietary Patent Medicine Vendors (PPMVs) that represent the main source of medicines for most Nigerians, these price increases mean there is added pressure to balance the need to provide lifesaving medicines to their communities and the need to run their businesses effectively.

There is also the challenge of an opaque supply chain where manufacturers have limited or delayed visibility into what is happening on the frontlines, which means pharmacies and PPMVs are often left to make do with what they can get rather than what they need.

By leveraging Remedial Health’s tech-enabled platform, neighborhood pharmacies, PPMVs and hospitals can benefit from group/bulk buying discounts, time-saving and improved efficiency, access to credit to improve their earnings, and additional revenue from providing financial services and other primary healthcare services.

Manufacturers also benefit from an efficient supply chain, a clear and instant route-to-market for their products and real-time intelligence on product utilization to improve decision-making on forecasting, production and distribution.

Speaking for the participants, Sacha Haider, Principal at Global Ventures, said, “The team at Remedial Health is proactively addressing challenges including price opacity, poor drug quality control and a very fragmented supply chain, head on to create a tech-enabled, pharmacy -centered healthcare network that has allowed over 25 per cent in cost reductions at the point of care.

“We are excited to partner with Sam on his mission to improve access to quality and affordable healthcare in Africa through optimized pharmaceutical supply chains.”

Leave a Comment

Your email address will not be published. Required fields are marked *